Thomas Mercier
Overview
Explore the profile of Thomas Mercier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
237
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bertin S, Versace F, Mercier T, Murisier A, Sauvain G, Haefliger D, et al.
J Pharm Biomed Anal
. 2024 Dec;
255():116612.
PMID: 39721342
Levosimendan is a positive inotrope and vasodilator used in patients with acute and chronic decompensated heart failure. It is metabolized into OR-1855 (inactive metabolite), which is further acetylated into OR-1896...
2.
Cancela Costa A, Kritikos A, Glampedakis E, Da Silva Pereira Clara J, Schaller F, Mercier T, et al.
J Antimicrob Chemother
. 2024 May;
79(7):1668-1672.
PMID: 38785349
Background: Invasive fungal infections (IFIs) are severe and difficult-to-treat infections affecting immunocompromised patients. Antifungal drug penetration at the site of infection is critical for outcome and may be difficult to...
3.
Bongiovanni M, Thoueille P, Barda B, Mercier T, Marzolini C, Ramponi N, et al.
Eur J Clin Microbiol Infect Dis
. 2024 May;
43(7):1503-1504.
PMID: 38740656
No abstract available.
4.
Tachet J, Versace F, Mercier T, Buclin T, Decosterd L, Choong E, et al.
J Chromatogr B Analyt Technol Biomed Life Sci
. 2023 Nov;
1230:123917.
PMID: 37956468
Janus kinase inhibitors (JAKi) are oral small molecules used in the treatment of a broad spectrum of autoimmune and myeloproliferative diseases. JAKi exhibit significant intra- and inter-individual pharmacokinetic variabilities, due...
5.
de Groote P, Delobelle M, Hebbar E, Mercier T, Fertin M, Goeminne C, et al.
Arch Cardiovasc Dis
. 2022 Mar;
115(3):169-178.
PMID: 35283039
Background: Previous studies have shown that pulmonary hypertension is a predictor of mortality in patients with systolic heart failure (SHF). Persistent pulmonary hypertension after a reactivity test is associated with...
6.
Zheng A, Dubuis G, Georgieva M, Mendes Ferreira C, Serulla M, Conde Rubio M, et al.
J Cell Sci
. 2022 Jan;
135(5).
PMID: 34981808
High-density lipoproteins (HDLs) prevent cell death induced by a variety of cytotoxic drugs. The underlying mechanisms are however still poorly understood. Here, we present evidence that HDLs efficiently protect cells...
7.
Gallay J, ProdHom S, Mercier T, Bardinet C, Spaggiari D, Pothin E, et al.
J Pharm Biomed Anal
. 2020 Feb;
182:112759.
PMID: 32063409
No abstract available.
8.
Dao K, Thoueille P, Decosterd L, Mercier T, Guidi M, Bardinet C, et al.
Pharmacol Res Perspect
. 2020 Jan;
8(1):e00558.
PMID: 31990440
A pilot study was conducted aiming at specifying sultiame's pharmacokinetic profile, completed by in vitro assays evaluating the intraerythrocytic transfer of sultiame and by a pharmacokinetic model assessing its distribution....
9.
Krishnan C, Mercier T, Rahman T, Piana G, Brossard M, Yagafarov T, et al.
Nanoscale
. 2019 Oct;
11(40):18837-18844.
PMID: 31595913
In this paper, we propose a hybrid quantum dot (QD)/solar cell configuration to improve performance of interdigitated back contact (IBC) silicon solar cells, resulting in 39.5% relative boost in the...
10.
Perez Marin M, Decosterd L, Andre P, Buclin T, Mercier T, Murray K, et al.
J Pediatric Infect Dis Soc
. 2019 Jun;
9(1):96-99.
PMID: 31183500
Little information on the efficacy and pharmacokinetics of letermovir among immunocompromised children is currently available. We describe here the use of letermovir in a 2-year-old immunocompromised child with ganciclovir-resistant cytomegalovirus...